证券日报网讯2月5日，万泰生物（603392）在互动平台回答投资者提问时表示，公司重组三价轮状病毒 亚单位疫苗(大肠埃希菌)采用全新的技术路线，从理论角度分析，具有更广的保护范围。 ...

Group 1 - The core announcement is that Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has received acceptance for its clinical trial application for the recombinant trivalent rotavirus subunit vaccine (E. coli) from the National Medical Products Administration [1][2] - The vaccine is developed in collaboration with Xiamen University and is designed to prevent rotavirus gastroenteritis, utilizing a recombinant protein vaccine technology based on an E. coli expression system [1][2] - The company has invested approximately 65.85 million RMB in the development of this vaccine project as of November 30, 2025 [2] Group 2 - The acceptance of the clinical trial application marks a significant step in the company's innovative vaccine development process, enhancing its product portfolio and market competitiveness [2] - The company has also announced the approval of an HIV antibody oral mucosal exudate self-test kit, which is the first of its kind in China, further establishing its leadership in the HIV self-testing market [7][8] - This HIV self-test kit is expected to improve accessibility to HIV testing and contribute to public health efforts, aligning with national strategies for HIV prevention and control [9][10]

Core Viewpoint - The acceptance of the clinical trial application for the "recombinant trivalent rotavirus subunit vaccine (E. coli)" marks a significant milestone in the company's innovative vaccine development process, indicating progress in its recombinant protein vaccine strategy based on its E. coli technology platform [1] Group 1 - The clinical trial application for the vaccine has been accepted by the National Medical Products Administration [1] - The vaccine is intended for the prevention of rotavirus gastroenteritis [1] - Successful development and future market launch of this product could enhance the company's product portfolio and increase its market competitiveness [1]